Patient Square Capital, a healthcare investment firm based in Menlo Park, Calif., has led a $71 million series B round of financing in Resolve Biosciences, a Molecular Cartography technology company.

Resolve’s Molecular Cartography technology provides high-resolution views of subcellular, single-molecule biology, looking to help researchers gain new insights related to Covid-19 pathology as well as neurology, oncology and developmental biography. EDBI, PS Capital, Alafi Capital, and NRW.Bank also participated in this round of funding, as well as other existing investors. The company has now raised over $100 million.

“This series B financing is another strong validation of our mission, our technology, and our team,” comments Jason Gammack, co-founder and CEO of Resolve Biosciences. “We look forward to working with the Patient Square Capital team and empowering more visionary scientists with the tools to solve biology’s greatest challenges.”